Genome-wide association studies have identified several subgroups of medulloblastoma; however, few druggable targets have emerged. G-protein coupled receptors (GPCRs) possess characteristics that make them ideal targets for molecular imaging and therapeutics; drugs targeting GPCRs account for 30-40% of all current pharmaceuticals. While expression patterns of many proteins in human medulloblast...

FDG PET/CT as a molecular imaging modality detected spinal cord metastases in a patient with medulloblastoma. Increased FDG uptake was reported as negatively correlated with survival in medulloblastoma in the literature. Although, spinal cord metastases associated with medulloblastoma detected with FDG-PET/CT imaging is a rare condition. To the best of our knowledge, this is the first report on...

BACKGROUND AND PURPOSE Medulloblastoma is one of the most common posterior fossa tumors to occur in children. Our purpose was to document the frequency, location, and time of occurrence of intracranial calcifications in cranial CT studies of children with medulloblastoma. METHODS We retrospectively reviewed cranial CT studies of 56 patients diagnosed with medulloblastoma from 1983 through 199...

craniospinal irradiation plus posterior fossa boost (cs1) is the standard modality of post-operative treatment of patient with medulloblastoma, but considering the technical difficulties and limited facilities, often whole- brain irradiation plus posterior fossa boost (wbi) had been used in our institution until 1991. tust a retrospective study was undertaken to compare the patients treated by ...

AIM To identify and characterize the subunit structure of interleukin-13 receptor (IL-13R) in human medulloblastoma cell lines and target them with a chimeric fusion protein consisting of interleukin-13 and Pseudomonas exotoxin (termed as IL-13 cytotoxin). METHODS Five human medulloblastoma cell lines were examined for the expression of IL-13R subunits at the mRNA and protein levels by revers...

Medulloblastoma is a cancer of the cerebellum, for which there is currently no approved targeted therapy. Recent transcriptomics approaches have demonstrated that medulloblastoma is composed of molecularly distinct subgroups, one of which is characterized by activation of the Hedgehog pathway, which in mouse models is sufficient to drive medulloblastoma development. There is thus considerable i...

Treatment for medulloblastoma, the most common malignant brain tumor in children, remains limited to surgical resection, radiation, and traditional chemotherapy; with long-term survival as low as 50-60% for Sonic Hedgehog (Shh)-type medulloblastoma. We have shown that the transcription factor Atonal homologue 1 (Atoh1) is required for Shh-type medulloblastoma development in mice. To determine w...